Last update 01 Nov 2024
Neugen LLC

Neugen LLC

Startups
|
Private Company|
2018|
Wisconsin, United States
|
100-250
|
www.neugenhealth.com

Overview

Related

3
Drugs associated with Neugen LLC
WN-1316
Target
Nrf2
Mechanism
Nrf2 stimulants [+1]
Active Org.
Wakunaga Pharmaceutical Co., Ltd.Wakunaga Pharmaceutical Co., Ltd.
Originator Org.
Wakunaga Pharmaceutical Co., Ltd.Wakunaga Pharmaceutical Co., Ltd.
Active Indication
Amyotrophic Lateral Sclerosis
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
NDDPX-08
Target
D2 receptor
Mechanism
D2 receptor agonists
Active Org.-
Originator Org.
Neugen LLCNeugen LLCStartup
Active Indication-
Inactive Indication
Amyotrophic Lateral Sclerosis
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date-
NGD-961
Target
GABAA receptor
Mechanism
GABAA receptor agonists
Active Org.-
Originator Org.
Neugen LLCNeugen LLCStartup
Active Indication-
Inactive Indication
Sleep Initiation and Maintenance Disorders
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date-
100 Clinical Results associated with Neugen LLC
Login to view more data
0 Patents (Medical) associated with Neugen LLC
Login to view more data
100 Deals associated with Neugen LLC
Login to view more data
100 Translational Medicine associated with Neugen LLC
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Other
3
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
NGD-961
 ( GABAA receptor )		Sleep Initiation and Maintenance Disorders
More
Discontinued
NDDPX-08
 ( D2 receptor )		Amyotrophic Lateral Sclerosis
More
Discontinued
WN-1316
 ( Nrf2 )		Amyotrophic Lateral Sclerosis
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free